Isovorin (Levoleucovorin)

Levoleucovorin provides a reduced form of folate that bypasses dihydrofolate reductase inhibition, allowing normal cells to continue DNA synthesis while supporting the cytotoxic action of fluoropyrimidine agents and reducing methotrexate‑related toxicity.

The dose of Isovorin is determined by the prescribing clinician based on the specific indication, patient weight, renal function, and the chemotherapy regimen being supported. Exact dosing instructions are provided on the prescription.

Safety data for levoleucovorin in pregnancy and lactation are limited. The product’s pregnancy category is unknown, so it should only be used if the potential benefit justifies the potential risk to the fetus or infant, and under close medical supervision.

To order Isovorin, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Isovorin (levoleucovorin) is a stereoisomer of leucovorin that offers a higher affinity for cellular uptake, potentially providing more efficient folate rescue. Compared with standard leucovorin, it may achieve similar clinical outcomes at lower concentrations, but choice depends on physician preference, formulation availability, and specific treatment protocols.

Isovorin should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the solution. Keep the product in its original packaging until ready for use to maintain stability.

Isovorin is administered by intravenous or intramuscular injection under aseptic conditions. The route, infusion rate, and timing relative to chemotherapy are determined by the treating oncologist and follow institutional protocols.

Serious risks include severe allergic reactions such as anaphylaxis, acute renal failure, severe hepatic dysfunction, life‑threatening hypotension, and rare thromboembolic events. Patients should be monitored closely for any signs of these reactions during and after administration.

Isovorin is contraindicated in patients with known hypersensitivity to levoleucovorin or other folate analogues. Caution is also advised for individuals with severe renal or hepatic impairment, and it should be avoided in pregnant or breastfeeding women unless clearly indicated by a specialist.